USA flag logo/image

An Official Website of the United States Government

WILDLIFE ORAL VACCINE AGAINST B. BURGDORFERI

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
71189
Program Year/Program:
2004 / SBIR
Agency Tracking Number:
AI058364
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
BIOPEPTIDES, INC.
18 WOODHULL RD EAST SETAUKET, NY -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2004
Title: WILDLIFE ORAL VACCINE AGAINST B. BURGDORFERI
Agency: HHS
Contract: 1R44AI058364-01A1
Award Amount: $147,863.00
 

Abstract:

DESCRIPTION (provided by applicant): Lyme disease is a significant public health treat, it is the most prevalent vector borne infectious disease in the United States, and its geographical range is expanding. The white-footed mouse is the major natural reservoir of Borrelia burgdorferi, the etiological agent of Lyme disease. Ixodes scapularis ticks acquire B. burgdorferi from infected mice (and other wildlife reservoirs) and transmit it to uninfected mice. This cycle maintains the zoonosis in endemic areas. Breaking the mouse-tick cycle by eliminating B. burgdorferi from its mouse reservoir and/or from the ticks that feed on them would markedly reduce the risk of Lyme disease. The goal of this proposal is to develop an oral immunization delivery system that can be safely deployed into the wild in endemic areas to vaccinate vertebrates known to be reservoir hosts for B. burgdorferi therefore breaking the enzootic cycle of this pathogen. In Phase I of this SBIR we proposed to develop an oral wildlife bait vaccine comprised of OspA, and if effective, OspC/OspA, using E. coli as a freeze-dried vehicle for immunogen delivery. In this Phase II proposal, the vaccine formulation developed in Phase I will be delivered orally to Lyme disease susceptible inbred mice. First, mice will be immunized by oral gavage inoculation and subsequently challenged by B. burgdorferi infected I.scapularis (nymphs). Second, a bait vaccine will be tested by admixing mouse chow with freeze-dried E. coli expressing the immunogen and challenging the mice as described above. Additionally, we will begin performance testing required for regulatory review. The development of an inexpensive, highly specific, effective, and easily distributable vaccine to decrease the prevalence of B. burgdorferi in tick populations around human communities could significantly reduce the incidence of Lyme disease cases within the several years of its introduction and will lead to the indirect control of human Lyme disease.

Principal Investigator:

Maria J. Gomessolecki
6316324284
MGOMESSOLECK@NOTES.CC.SUNYSB.EDU

Business Contact:


6316324284
Small Business Information at Submission:

BIOPEPTIDES, INC.
BIOPEPTIDES, INC. BOX 111, 25 E LOOP RD STONY BROOK, NY 11790

EIN/Tax ID: 113601189
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No